Immunotherapy in lung cancer. [Review] 

 -  2021 
<br/><br/> Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. Copyright (c) 2020 Wiley Periodicals LLC. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0022-4790 
<br/><br/><label>Standard No.: </label>10.1002/jso.26347 [doi] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>IN PROCESS -- NOT YET INDEXED
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Hematology/Oncology<br/>Medicine/General Internal Medicine
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review